Cannabis & Psychedelics Articles
Ontario Announces Delays to Retail Cannabis Sales
The delay is to provide time to create a framework that will regulate independently-run retail outlets as opposed to having the previously agreed state-run retail setup.
Cannabis Concentrate Use Linked to Cannabis Use Disorder
Self-reporting study fuels debate over the potential risks to mental health of long term, high THC concentrate use.
Cannabis Oil Shows Promise as Treatment for Untreatable Childhood Epilepsy
A clinical trial involving 20 Canadian children with severe intractable epilepsy has posted resulting indicating cannabis oil could reduce seizures by over 70%.
The Evolution of Cannabis Testing and the Science of Cannabis
Dr. Jeffrey Raber is proud to be speaking at The Science of Cannabis 2018 about the past, present and future challenges encountered by the cannabis testing industry.
Colorado’s Cannabis Growers Will Shoulder the Cost of New Regulations
New legislation brought in by the Colorado Marijuana Enforcement Division, in effect from August 1st, requires mandatory pesticide testing on all strains of cannabis flower and trim that is sold in the state adding increased testing costs for producers.
Saliva Screening as an Effective Method for Cannabis Use Detection
By analyzing the THC content of a saliva sample, researchers have found that it is possible to accurately determine if someone has used cannabis via smoking, vaporization or ingestion of edibles, within the past 24 hours.
A Look Inside the Massachusetts Cannabis Testing Controversy
Two cannabis testing facilities have now been issued provisional licenses in the state but the debate over their differing approaches to microbiological contamination testing continues.
Beer Makers Look to Cash in on Legal Cannabis Market
The brewer behind Corona and Modelo beer has just made a $4 billion investment in Canopy Growth representing the largest investment in the cannabis industry to date.
New Cannabis Regulations to Become UK Law within 2 Years
This development comes at a disruptive time for UK cannabis regulations, as the drug has only recently been moved to a schedule 2 classification under the 2001 Misuse of Drugs Regulations act, allowing clinicians to prescribe it by the fall.
